Variations in Oncologist Recommendations for Chemotherapy for Stage IV Lung Cancer: What Is the Role of Performance Status? - Wikidata - awgldk - TriplyDB

Variations in Oncologist Recommendations for Chemotherapy for Stage IV Lung Cancer: What Is the Role of Performance Status?

Variations in Oncologist Recommendations for Chemotherapy for Stage IV Lung Cancer: What Is the Role of Performance Status?

http://www.wikidata.org/entity/Q37117859

about

Association between physician medical school ranking and patient outcomes and costs of care: observational study

P2860

Q58696374-EDAEDA18-E606-4BC6-BE5B-6A0F46A06A29

P2860

Variations in Oncologist Recommendations for Chemotherapy for Stage IV Lung Cancer: What Is the Role of Performance Status?

http://www.wikidata.org/entity/Q37117859

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 07 June 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Variations in Oncologist Recom ...... he Role of Performance Status?

@en

Variations in Oncologist Recom ...... he Role of Performance Status?

@nl

type

label

Variations in Oncologist Recom ...... he Role of Performance Status?

@en

Variations in Oncologist Recom ...... he Role of Performance Status?

@nl

prefLabel

Variations in Oncologist Recom ...... he Role of Performance Status?

@en

Variations in Oncologist Recom ...... he Role of Performance Status?

@nl

P1433

Q37117859-B7288F48-DB18-4DEC-A079-D7A5889C9D21

P1476

Q37117859-AAB1A2DC-D746-4941-945F-BDCC71F51269

P2093

Q37117859-0BCFF226-CC93-4034-BCEC-19FD7C767A01

Q37117859-18D7CD0C-2191-40A7-B6DA-CF3354918C71

Q37117859-2646C454-BC55-48DB-BC2D-F7850C0CBC21

Q37117859-3C24C04A-6CD8-4AD1-82AD-634236A1AA82

Q37117859-72231F26-0140-4DC1-91B4-AFDCE1EB12E0

Q37117859-81351496-ADA3-4921-8DCC-2D85135F40FE

Q37117859-9CFDD403-6DAD-4F44-9DF2-AD1A8B0CCA30

Q37117859-A883E212-0C6C-4F1C-B65B-A5416BCC047F

Q37117859-F77C6ADD-51FA-4718-BEB8-F9A015A790BB

P2860

Q37117859-073AC053-84B7-433A-AE56-0C1157A1CF29

Q37117859-175AEE2F-8423-486C-8F2C-DFFEE895D4FE

Q37117859-2CD5ADD8-B0D3-431B-A703-45B0F5741D76

Q37117859-2DF7D0DF-E207-4141-A291-8383BF775040

Q37117859-39A14F2E-27E6-4F5D-B938-E8D2966C92FF

Q37117859-3C5C7E48-F6C4-4A8D-87B3-E06D168F6B05

Q37117859-3F01E4C6-28A7-493A-96AC-368ACD0FE308

Q37117859-47C26AC0-6BEA-4AFA-946B-EB6D825797BD

Q37117859-4CB0069F-5410-41A9-A0F5-3821AB200A31

Q37117859-505403FF-E196-48DC-A59B-15605E3F140E

P304

Q37117859-9F2757EA-4A26-4AFA-8342-C5C2EA24F110

P31

Q37117859-50A79295-C0AD-426E-89CC-0DE9C63AFD56

P356

Q37117859-69907094-9897-4996-BBD4-9091F125EC0C

P407

Q37117859-9A186655-83D3-465B-A2A3-6BFC9EC4FFD2

P433

Q37117859-AB6F2F67-A5AA-4E62-BD7F-F9F1388B3EEE

P478

Q37117859-3D4C0AD3-5024-43A5-BB4F-DDFD6B9B3E99

P577

Q37117859-1DADF66E-1958-4AD7-9FDB-8852DCE5D745

P698

Q37117859-E61F9594-FD88-4F94-BB24-C1E4FF3BEB37

P921

Q37117859-6A4DB73A-19E1-4C06-81E9-7928952F813C

P932

Q37117859-C175EA21-2DE1-48C8-9005-922AB48887CB

P356

JOP.2015.008425

P1433

Journal of Oncology Practice

P1476

Variations in Oncologist Recom ...... he Role of Performance Status?

@en

P2093

Carrie Klabunde

http://www.w3.org/2001/XMLSchema#string

Diana Tisnado

http://www.w3.org/2001/XMLSchema#string

Jennifer Malin

http://www.w3.org/2001/XMLSchema#string

Katherine Kahn

http://www.w3.org/2001/XMLSchema#string

Mary Beth Landrum

http://www.w3.org/2001/XMLSchema#string

Nancy L Keating

http://www.w3.org/2001/XMLSchema#string

Robert Fletcher

http://www.w3.org/2001/XMLSchema#string

Selwyn O Rogers

http://www.w3.org/2001/XMLSchema#string

Steven Clauser

http://www.w3.org/2001/XMLSchema#string

P2860

Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease

Patients' expectations about effects of chemotherapy for advanced cancer

Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials

Longitudinal data analysis for discrete and continuous outcomes

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

Early palliative care for patients with metastatic non-small-cell lung cancer

Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting.

Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials

Multiple imputation in a large-scale complex survey: a practical guide.

Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature.

P304

653-662

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JOP.2015.008425

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27271507

http://www.w3.org/2001/XMLSchema#string

P921

P932

4957251

http://www.w3.org/2001/XMLSchema#string